[en] Context: Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once-monthly oral dosing. Objective: The purpose of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of once-monthly oral ibandronate. Design: A randomized, 3-month, double-blind, placebo-controlled, phase I study (Monthly Oral Pilot Study) was conducted. Setting: The study was conducted at five clinical trial centers in the United Kingdom and Belgium. Patients or Other Participants: Subjects were postmenopausal women (age, 55 - 80 yr; >= 3 yr post menopause; n = 144). Intervention(s): Once-monthly oral ibandronate 50, 100, or 150 mg or placebo was used. After the first cycle, the 50-mg arm was split, with participants continuing on either 50 or 100 mg. Main Outcome Measure(s): Primary outcome measures were safety, serum and urinary C-telopeptide (CTX), and serum ibandronate AUC(0-infinity). Results: Once- monthly oral ibandronate was well tolerated, with a similar overall and upper gastrointestinal safety profile to placebo. Once- monthly ibandronate was also highly effective in decreasing bone turnover; substantial reductions from baseline in serum CTX (-56.7% and -40.7% in the 150- and 100- mg arms, respectively; P < 0.001 vs. placebo) and urinary CTX (-54.1% and -34.6%, respectively; P < 0.001 vs. placebo) were observed at d 91 (30 d after the final dose). Analysis of the area under the effect curve (d1 - 91) for change from baseline (percent x days) in serum CTX and urinary CTX indicated a dose- response relationship. The AUC(0-infinity) for ibandronate increased with dose but not in a dose- proportional manner. Conclusions: These findings indicate a potential role for once-monthly oral ibandronate in the treatment of postmenopausal osteoporosis.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Wilson, K. M.
Dumont, Etienne
Bonvoisin, B.
Barrett, J.
Language :
English
Title :
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study
Publication date :
September 2005
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Soc, Chevy Chase, United States - Maryland
Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D 1997 Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7:390-406
Melton LJ, Atkinson EJ, O'Fallon WM, Walmer HW, Riggs BL 1991 Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites. J Bone Miner Res 6(Suppl 1):S136 (Abstract)
Melton LJ 2003 Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18:1139-1141
Chrischilles EA, Butler CD, Davis CS, Wallace RB 1991 A model of lifetime osteoporosis impact. Arch Intern Med 151:2026-2032
Greendale GA, Barrett-Connor E, Ingles S, Haile R 1995 Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 43:955-961
Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon M, Melton LJ 1993 Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001-1005
Browner WS, Pressman AR, Nevitt MC, Cummings SR 1996 Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 156:1521-1525
Ismail AA, O'Neill TW, Cooper C, Finn JD, Bhalla AK, Cannata JB, Delmas P, Falch JA, Felsch B, Hoszowski K, Johnell O, Diaz-Lopez JB, Lopez Vaz A, Marchand F, Raspe H, Reid DM, Todd C, Weber K, Woolf A, Reeve J, Silman AJ 1998 Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 8:291-297
Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O 2003 Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61-68
International Osteoporosis Foundation 2001 Osteoporosis in the European community: a call to action.
Ray NF, Chan JK, Thamer M, Melton LJ 1997 Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35
Cramer JA, Amonkar MM, Hebborn A, Suppapanya N 2004 Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? J Bone Miner Res 19(Suppl 1):S448 (Abstract)
Ettinger MP, Gallagher R, Amonkar MM, Smith JC, MacCosbe PE 2004 Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 50(Suppl):S513 (Abstract)
Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH 2003 Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808-813
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E 2003 Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
Clowes JA, Peel NFA, Eastell R 2004 The impact of monitoring adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123
McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
Eastell R, Garnero P, Vrijens B, van de Langerijt L, Pols HAP, Ringe JD, Roux C, Watts NB, Cahall D, Delmas PD 2003 Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:408
Claxton AJ, Cramer J, Pierce C 2001 A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310
Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora 2nd AC, Kaur A, Thompson DE, Yates J, Orloff JJ 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1-12
Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111
Simon JA, Lewiecki M, Smith ME, Petruschke RA, Wang L, Palmisano JJ 2002 Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter randomized open-label, crossover study. Clin Ther 24:1871-1886
Kendler D, Kung AW, Fuleihan Gel-H, Gonzalez Gonzalez JG, Gaines KA, Verbruggen N, Melton ME 2004 Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243-251
Bauss F, Russell G 2004 Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423-433
Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
Gieschke R, Reginster J-Y 2004 Successful prediction of the effect of oncemonthly oral ibandronate on a marker of bone resorption using clinical trial simulation (CTS). Osteoporos Int 15(Suppl 1):S97 (Abstract)
Delmas PD, Recker RR, Chesnut CH, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792-798
Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C 2001 Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871-1878
Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, Schimmer RC 2003 Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:4609-4615
Ravn P, Clemmesen B, Riis BJ, Christiansen C 1996 The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1 year, randomized, double-blind, placebo controlled dose finding study. Bone 19:527-533
McClung MR, Wasnich RD, Recker RR, Cauley JA, Chesnut 3rd CH, Ensrud KE, Burdeska A, Mills T 2004 Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 9:11-18
Tanko LB, Felsenberg D, Czerwinski E, Burdeska A, Jonkanski I, Hughes C, Christiansen C 2003 Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 254:159-167
Diel IJ, Body JJ, Tripathy D, Bergstrom B 2003 Oral daily ibandronate in women with metastatic breast cancer: a pooled safety analysis. Proc Am Soc Clin Oncol 22:47 (Abstract)
Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG 1995 Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298
Mitchell DY, Eusebio RA, Sacco-Gibson NA, Pallone KA, Kelly SC, Nesbitt JD, Brezovic CP, Thompson GA, Powell JH 2000 Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 40:258-265
Barrett J, Worth E, Bauss F, Epstein S 2004 Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951-965
Lombas C, Hakim C, Zanchetta JR 2000 Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15(Suppl 1):M406 (Abstract)
Segal E, Tamir A, Ish-Shalom S 2003 Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859-862
Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B 2003 Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216